Published in Epidemiol Rev on January 01, 2014
Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. JAMA Oncol (2015) 3.64
Obesity and cancer: mechanistic insights from transdisciplinary studies. Endocr Relat Cancer (2015) 0.96
Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium. Breast Cancer Res Treat (2015) 0.95
Racial and Ethnic Disparities in the Impact of Obesity on Breast Cancer Risk and Survival: A Global Perspective. Adv Nutr (2015) 0.93
Overall and central adiposity and breast cancer risk in the sister study. Cancer (2015) 0.90
Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Med (2016) 0.87
Body size throughout adult life influences postmenopausal breast cancer risk among hispanic women: the breast cancer health disparities study. Cancer Epidemiol Biomarkers Prev (2014) 0.87
Preliminary evaluation of the publicly available Laboratory for Breast Radiodensity Assessment (LIBRA) software tool: comparison of fully automated area and volumetric density measures in a case-control study with digital mammography. Breast Cancer Res (2015) 0.87
Association of high obesity with PAM50 breast cancer intrinsic subtypes and gene expression. BMC Cancer (2015) 0.83
Variation in Breast Cancer-Risk Factor Associations by Method of Detection: Results From a Series of Case-Control Studies. Am J Epidemiol (2015) 0.83
Body Mass Index at Diagnosis and Breast Cancer Survival Prognosis in Clinical Trial Populations from NRG Oncology/NSABP B-30, B-31, B-34, and B-38. Cancer Epidemiol Biomarkers Prev (2015) 0.81
Modification of breast cancer risk according to age and menopausal status: a combined analysis of five population-based case-control studies. Breast Cancer Res Treat (2014) 0.81
Risk factors for young-onset invasive and in situ breast cancer. Cancer Causes Control (2015) 0.77
Time-restricted feeding improves insulin resistance and hepatic steatosis in a mouse model of postmenopausal obesity. Metabolism (2016) 0.77
Energy-Related Indicators and Breast Cancer Risk among White and Black Women. PLoS One (2015) 0.76
Genetic variants in the mTOR pathway and interaction with body size and weight gain on breast cancer risk in African-American and European American women. Cancer Causes Control (2016) 0.76
Circulating gamma-glutamyl transferase and development of specific breast cancer subtypes: findings from the Apolipoprotein Mortality Risk (AMORIS) cohort. Breast Cancer Res (2017) 0.75
Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes. Ann Intern Med (2016) 0.75
Outcome of Breast Cancer in Moroccan Young Women Correlated to Clinic-Pathological Features, Risk Factors and Treatment: A Comparative Study of 716 Cases in a Single Institution. PLoS One (2016) 0.75
Lifetime body size and estrogen-receptor-positive breast cancer risk in the California Teachers Study cohort. Breast Cancer Res (2016) 0.75
Effects of lifestyle modification after breast cancer treatment: a systematic review protocol. Syst Rev (2014) 0.75
Effects of Erythrocyte Membrane Polyunsaturated Fatty Acids in Overweight, Obese, and Morbidly Obese Korean Women. J Cancer Prev (2017) 0.75
Hormone factors play a favorable role in female head and neck cancer risk. Cancer Med (2017) 0.75
The Androgen Receptor Supports Tumor Progression After the Loss of Ovarian Function in a Preclinical Model of Obesity and Breast Cancer. Horm Cancer (2017) 0.75
Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention. CA Cancer J Clin (2017) 0.75
Meta-analysis in clinical trials. Control Clin Trials (1986) 144.91
Bias in meta-analysis detected by a simple, graphical test. BMJ (1997) 122.24
Quantifying heterogeneity in a meta-analysis. Stat Med (2002) 83.16
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser (2000) 70.59
Operating characteristics of a rank correlation test for publication bias. Biometrics (1994) 47.97
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
The obesity epidemic in the United States--gender, age, socioeconomic, racial/ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev (2007) 16.67
Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol (2001) 12.72
Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood) (2009) 12.45
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Health and economic burden of the projected obesity trends in the USA and the UK. Lancet (2011) 10.73
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Validity of self-reported waist and hip circumferences in men and women. Epidemiology (1990) 10.57
Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst (2002) 9.65
Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ (2007) 8.00
Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol (2000) 7.95
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ (2001) 7.13
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med (2004) 6.42
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst (2003) 6.20
Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev (2004) 5.32
Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst (2006) 5.17
Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst (2007) 5.08
Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol (2000) 4.83
Dual effects of weight and weight gain on breast cancer risk. JAMA (1997) 4.81
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
The reliability and validity of self-reported weight and height. J Chronic Dis (1982) 4.39
The accuracy of self-reported weights. Am J Clin Nutr (1981) 4.28
Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann Intern Med (2012) 4.17
Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst (2011) 4.14
Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst (1996) 3.76
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control (2002) 3.27
Hormone replacement therapy in relation to breast cancer. JAMA (2002) 3.14
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA (2002) 3.13
Adult weight change and risk of postmenopausal breast cancer. JAMA (2006) 3.11
Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer (2004) 2.96
Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol (2000) 2.93
Agreement between interview information and physician records on history of menopausal estrogen use. Am J Epidemiol (1990) 2.71
State-specific prevalence of obesity among adults--United States, 2005. MMWR Morb Mortal Wkly Rep (2006) 2.58
Adipose tissue as a source of hormones. Am J Clin Nutr (1987) 2.57
Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab (2006) 2.52
Remote recall of childhood height, weight, and body build by elderly subjects. Am J Epidemiol (1993) 2.49
Body size, mammographic density, and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2006) 2.44
Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women. Breast Cancer Res Treat (2007) 2.41
Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev (2004) 2.40
Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol (1994) 2.37
Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst (2007) 2.36
Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer (2005) 2.32
Hormone therapy prescribing patterns in the United States. Obstet Gynecol (2004) 2.29
Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev (2004) 2.27
Hormone replacement therapy use and variations in the risk of breast cancer. BJOG (2008) 2.24
Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med (2007) 2.23
Central obesity and breast cancer risk: a systematic review. Obes Rev (2003) 2.16
Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol Biomarkers Prev (2003) 2.14
A prospective study of body size in different periods of life and risk of premenopausal breast cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.97
Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol (2006) 1.96
Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev (2008) 1.88
Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med (2006) 1.88
Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis. Int J Cancer (2009) 1.88
Body size in different periods of life and breast cancer risk in post-menopausal women. Int J Cancer (1998) 1.86
Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer (2000) 1.83
Abdominal obesity and breast cancer risk. Ann Intern Med (1990) 1.83
Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? J Clin Oncol (2002) 1.82
Prospective study of relative weight, height, and risk of breast cancer. JAMA (1989) 1.82
Consumption of meat, animal products, protein, and fat and risk of breast cancer: a prospective cohort study in New York. Epidemiology (1994) 1.82
Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev (2005) 1.81
A prospective study of body size and breast cancer in black women. Cancer Epidemiol Biomarkers Prev (2007) 1.77
Body size and breast cancer risk among women under age 45 years. Am J Epidemiol (1996) 1.75
Association of obesity and cancer risk in Canada. Am J Epidemiol (2004) 1.71
Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.67
A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol (2012) 1.67
Risk factors for hormone receptor-defined breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2006) 1.66
Accuracy and reliability of self-measurement of body girths. Am J Epidemiol (1988) 1.65
Body size and risk of breast cancer. Am J Epidemiol (1997) 1.63
Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev (2003) 1.63
Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol (1995) 1.59
Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol (2000) 1.58
Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 1.56
Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma. Cancer (2004) 1.56
Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control (2000) 1.56
Menopausal hormone therapy and breast cancer risk in the NIH-AARP Diet and Health Study Cohort. Cancer Epidemiol Biomarkers Prev (2008) 1.55
Waist circumference, waist:hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol (1999) 1.53
Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2008) 1.53
Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison. Breast Cancer Res (2006) 1.50
Hormone therapy and breast cancer: what factors modify the association? Menopause (2006) 1.49
Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy (2002) 1.46
Body size changes in relation to postmenopausal breast cancer among women on Long Island, New York. Am J Epidemiol (2005) 1.46
Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: a study within the EPIC cohort. Int J Cancer (2006) 1.43
A prospective study of breast cancer risk using routine mammographic breast density measurements. Cancer Epidemiol Biomarkers Prev (2004) 1.43
Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat (2010) 1.41
Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study. Int J Cancer (2006) 1.40
A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer (2002) 1.38
A case-control study of body mass index and breast cancer risk in white and African-American women. Cancer Epidemiol Biomarkers Prev (2010) 1.34
Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control (1994) 1.34
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med (2007) 9.34
Benefits and harms of CT screening for lung cancer: a systematic review. JAMA (2012) 8.71
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol (2013) 6.56
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med (2009) 5.68
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med (2009) 4.60
Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst (2009) 4.17
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05
Role of detection method in predicting breast cancer survival: analysis of randomized screening trials. J Natl Cancer Inst (2005) 4.01
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
Benefits, harms, and cost-effectiveness of supplemental ultrasonography screening for women with dense breasts. Ann Intern Med (2014) 3.46
Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol (2011) 3.40
Physical activity and survival after diagnosis of invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 3.11
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol (2012) 2.85
Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med (2012) 2.85
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials (2009) 2.79
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat (2011) 2.73
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
From menarche to menopause: trends among US Women born from 1912 to 1969. Am J Epidemiol (2006) 2.67
Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol (2011) 2.65
Alcohol consumption before and after breast cancer diagnosis: associations with survival from breast cancer, cardiovascular disease, and other causes. J Clin Oncol (2013) 2.46
Identifying women with dense breasts at high risk for interval cancer: a cohort study. Ann Intern Med (2015) 2.46
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol (2003) 2.41
The Wisconsin Breast Cancer Epidemiology Simulation Model. J Natl Cancer Inst Monogr (2006) 2.27
Geocoding addresses from a large population-based study: lessons learned. Epidemiology (2003) 2.27
Tension-dependent regulation of microtubule dynamics at kinetochores can explain metaphase congression in yeast. Mol Biol Cell (2005) 2.27
Socioeconomic risk factors for breast cancer: distinguishing individual- and community-level effects. Epidemiology (2004) 2.22
Retrospective cost-effectiveness analysis of screening mammography. J Natl Cancer Inst (2006) 2.19
Adaptive clinical trials: the promise and the caution. J Clin Oncol (2010) 2.15
Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol (2012) 2.07
Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk. Ann Intern Med (2012) 1.99
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med (2007) 1.94
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol (2007) 1.85
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol (2004) 1.83
Recruiting and training leadership through professional societies: a report from the American Society of Preventive Oncology Junior Members Interest Group. Cancer Epidemiol Biomarkers Prev (2006) 1.81
Thyroid cancer incidence and socioeconomic indicators of health care access. Cancer Causes Control (2008) 1.78
MDM2 promotes cell motility and invasiveness by regulating E-cadherin degradation. Mol Cell Biol (2006) 1.75
Body mass index before and after breast cancer diagnosis: associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiol Biomarkers Prev (2009) 1.75
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw (2009) 1.73
Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses. Arch Intern Med (2004) 1.69
A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol (2012) 1.67
Circulating serum xenoestrogens and mammographic breast density. Breast Cancer Res (2013) 1.65
Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer (2010) 1.62
A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study. Am J Surg (2009) 1.61
Cadmium exposure and breast cancer risk. J Natl Cancer Inst (2006) 1.61
Replication and functional genomic analyses of the breast cancer susceptibility locus at 6q25.1 generalize its importance in women of chinese, Japanese, and European ancestry. Cancer Res (2011) 1.59
Effects of birth order and maternal age on breast cancer risk: modification by whether women had been breast-fed. Epidemiology (2008) 1.56
Bedside clinical signs associated with impending death in patients with advanced cancer: preliminary findings of a prospective, longitudinal cohort study. Cancer (2015) 1.56
Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet (2011) 1.56
Lifetime recreational and occupational physical activity and risk of in situ and invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.56
Postmenopausal estrogen and progestin use in relation to breast cancer risk. Cancer Epidemiol Biomarkers Prev (2002) 1.56
Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. PLoS Genet (2013) 1.56
Adaptive clinical trials: a partial remedy for the therapeutic misconception? JAMA (2012) 1.54
Variation in tumor natural history contributes to racial disparities in breast cancer stage at diagnosis. Breast Cancer Res Treat (2013) 1.53
A parallel phase I/II clinical trial design for combination therapies. Biometrics (2007) 1.52
Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol (2005) 1.51
Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients. Cancer (2014) 1.49
Alcohol consumption and ovarian cancer risk in a population-based case-control study. Int J Cancer (2006) 1.48
Potential exposure to PCBs, DDT, and PBDEs from sport-caught fish consumption in relation to breast cancer risk in Wisconsin. Environ Health Perspect (2004) 1.47
Postoophorectomy estrogen use and breast cancer risk. Obstet Gynecol (2012) 1.46
Differences in breast cancer risk factors by tumor marker subtypes among premenopausal Vietnamese and Chinese women. Cancer Epidemiol Biomarkers Prev (2005) 1.45
Meta-analyses of colorectal cancer risk factors. Cancer Causes Control (2013) 1.42
Place of residence and primary treatment of prostate cancer: examining trends in rural and nonrural areas in Wisconsin. Urology (2013) 1.42
Prevalence and treatment of menopausal symptoms among breast cancer survivors. J Pain Symptom Manage (2002) 1.40
Duration of sleep and breast cancer risk in a large population-based case-control study. J Sleep Res (2006) 1.37
Quality of cancer registry data: findings from CDC-NPCR's Breast and Prostate Cancer Data Quality and Patterns of Care Study. J Registry Manag (2011) 1.35
Access to palliative care among patients treated at a comprehensive cancer center. Oncologist (2012) 1.34
Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control (2003) 1.32
An overview of the adaptive designs accelerating promising trials into treatments (ADAPT-IT) project. Ann Emerg Med (2012) 1.30
Rat Mcs5a is a compound quantitative trait locus with orthologous human loci that associate with breast cancer risk. Proc Natl Acad Sci U S A (2007) 1.29
Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials. Clin Trials (2013) 1.27
Prediagnostic use of hormone therapy and mortality after breast cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.25
From drug discovery to biomarker-driven clinical trials in lymphoma. Nat Rev Clin Oncol (2012) 1.24
Targeted agent use in cancer patients at the end of life. J Pain Symptom Manage (2012) 1.22
Health-related quality of life before and after a breast cancer diagnosis. Breast Cancer Res Treat (2007) 1.21
Early life factors in relation to breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev (2002) 1.20
The characteristics and training of professionals in cancer prevention and control: a survey of theAmerican Society for Preventive Oncology. Cancer Epidemiol Biomarkers Prev (2004) 1.18
Barriers and facilitators to implementing cancer survivorship care plans. Oncol Nurs Forum (2013) 1.18
Flawed inferences about screening mammography's benefit based on observational data. J Clin Oncol (2008) 1.17
Body mass index and the risk of death following the diagnosis of colorectal cancer in postmenopausal women (United States). Cancer Causes Control (2006) 1.17
Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. Am Heart J (2012) 1.17
Model Convolution: A Computational Approach to Digital Image Interpretation. Cell Mol Bioeng (2010) 1.15
Partner-regulated interaction of IFN regulatory factor 8 with chromatin visualized in live macrophages. Proc Natl Acad Sci U S A (2005) 1.14
Novel intraoperative molecular test for sentinel lymph node metastases in patients with early-stage breast cancer. J Clin Oncol (2008) 1.14
Quality of end-of-life care in patients with hematologic malignancies: a retrospective cohort study. Cancer (2014) 1.14
Oral contraceptive use, reproductive factors, and colorectal cancer risk: findings from Wisconsin. Cancer Epidemiol Biomarkers Prev (2005) 1.14
Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS One (2012) 1.13
Dynamic interactions of a transcription factor with DNA are accelerated by a chromatin remodeller. EMBO Rep (2004) 1.12
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev (2008) 1.12
Seamlessly expanding a randomized phase II trial to phase III. Biometrics (2002) 1.11
Social networks and quality of life among female long-term colorectal cancer survivors. Cancer (2003) 1.11
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat (2013) 1.10
A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug. Clin Trials (2010) 1.10